{"id":90544,"date":"2026-05-18T13:45:16","date_gmt":"2026-05-18T08:15:16","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=90544"},"modified":"2026-05-18T13:45:17","modified_gmt":"2026-05-18T08:15:17","slug":"marksans-pharma-analyst-review-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/marksans-pharma-analyst-review-2026\/","title":{"rendered":"Marksans Pharma Analyst Review May 2026"},"content":{"rendered":"<p>This <strong><a href=\"https:\/\/univest.in\/user\/stocks\/marksans\/marksans-pharma-ltd-share-price-today\">Marksans Pharma<\/a> analyst review<\/strong> for May 2026 covers the key data investors need for MARKSANS at its current price of Rs 213.40. Marksans Pharma (NSE: MARKSANS) is a specialty pharma company with a market capitalisation of approximately Rs 8,500 crore, focused on OTC pharmaceutical products in the US, UK, and Australia. The analyst consensus target of Rs 260 implies meaningful upside, and this <strong>Marksans Pharma analyst review<\/strong> examines technical levels, business performance, valuation, and key risks that will determine whether MARKSANS achieves that target through FY27.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-analyst-review-2026\/#Marksans_Pharma_Company_Snapshot_May_2026\" title=\"Marksans Pharma Company Snapshot May 2026\">Marksans Pharma Company Snapshot May 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-analyst-review-2026\/#Analyst_Insight_in_This_Marksans_Pharma_Analyst_Review\" title=\"Analyst Insight in This Marksans Pharma Analyst Review\">Analyst Insight in This Marksans Pharma Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-analyst-review-2026\/#Technical_Analysis_in_This_Marksans_Pharma_Analyst_Review\" title=\"Technical Analysis in This Marksans Pharma Analyst Review\">Technical Analysis in This Marksans Pharma Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-analyst-review-2026\/#Key_Support_and_Resistance_Levels\" title=\"Key Support and Resistance Levels\">Key Support and Resistance Levels<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-analyst-review-2026\/#Business_Segment_Analysis\" title=\"Business Segment Analysis\">Business Segment Analysis<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-analyst-review-2026\/#US_OTC_Pharmaceuticals_Acetaminophen_Ibuprofen\" title=\"US OTC Pharmaceuticals (Acetaminophen, Ibuprofen)\">US OTC Pharmaceuticals (Acetaminophen, Ibuprofen)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-analyst-review-2026\/#UK_and_European_OTC_Drug_Products\" title=\"UK and European OTC Drug Products\">UK and European OTC Drug Products<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-analyst-review-2026\/#Australia_and_New_Zealand_Regulated_Generics\" title=\"Australia and New Zealand Regulated Generics\">Australia and New Zealand Regulated Generics<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-analyst-review-2026\/#Valuation_in_This_Marksans_Pharma_Analyst_Review\" title=\"Valuation in This Marksans Pharma Analyst Review\">Valuation in This Marksans Pharma Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-analyst-review-2026\/#Trade_Outlook_for_Marksans_Pharma\" title=\"Trade Outlook for Marksans Pharma\">Trade Outlook for Marksans Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-analyst-review-2026\/#Key_Risks_for_Marksans_Pharma_in_FY27\" title=\"Key Risks for Marksans Pharma in FY27\">Key Risks for Marksans Pharma in FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-analyst-review-2026\/#Conclusion_Marksans_Pharma_Analyst_Review_Verdict_for_2026\" title=\"Conclusion: Marksans Pharma Analyst Review Verdict for 2026\">Conclusion: Marksans Pharma Analyst Review Verdict for 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-analyst-review-2026\/#Frequently_Asked_Questions_Marksans_Pharma_Analyst_Review_2026\" title=\"Frequently Asked Questions: Marksans Pharma Analyst Review 2026\">Frequently Asked Questions: Marksans Pharma Analyst Review 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-analyst-review-2026\/#What_is_the_analyst_target_for_Marksans_Pharma_in_2026\" title=\"What is the analyst target for Marksans Pharma in 2026?\">What is the analyst target for Marksans Pharma in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-analyst-review-2026\/#Is_Marksans_Pharma_a_good_investment_at_Rs_21340\" title=\"Is Marksans Pharma a good investment at Rs 213.40?\">Is Marksans Pharma a good investment at Rs 213.40?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-analyst-review-2026\/#What_is_Marksans_Pharmas_52-week_high_and_low\" title=\"What is Marksans Pharma&#8217;s 52-week high and low?\">What is Marksans Pharma&#8217;s 52-week high and low?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-analyst-review-2026\/#What_are_the_key_risks_for_Marksans_Pharma\" title=\"What are the key risks for Marksans Pharma?\">What are the key risks for Marksans Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-analyst-review-2026\/#Where_can_I_track_live_data_for_Marksans_Pharma\" title=\"Where can I track live data for Marksans Pharma?\">Where can I track live data for Marksans Pharma?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Marksans_Pharma_Company_Snapshot_May_2026\"><\/span><strong>Marksans Pharma Company Snapshot May 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Marksans&#8217; OTC-focused model in regulated markets (acetaminophen, ibuprofen, antacids, and anti-diarrhea products) provides steady recurring revenue. Manufacturing partnerships and direct OTC brand building in the UK are growth initiatives. The table below summarises the key data referenced in this <strong>Marksans Pharma analyst review<\/strong>.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Parameter<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>MARKSANS<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>Pharmaceuticals &#8211; Generic Formulations<\/td>\n<\/tr>\n<tr>\n<td>CMP (May 2026)<\/td>\n<td>Rs 213.40<\/td>\n<\/tr>\n<tr>\n<td>52 Week High<\/td>\n<td>Rs 270.70<\/td>\n<\/tr>\n<tr>\n<td>52 Week Low<\/td>\n<td>Rs 155.00<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 8,500 Crore<\/td>\n<\/tr>\n<tr>\n<td>Trailing P\/E<\/td>\n<td>25x<\/td>\n<\/tr>\n<tr>\n<td>Analyst Consensus Target<\/td>\n<td>Rs 260<\/td>\n<\/tr>\n<tr>\n<td>Bull Case Target<\/td>\n<td>Rs 320<\/td>\n<\/tr>\n<tr>\n<td>Bear Case Target<\/td>\n<td>Rs 165<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Analyst_Insight_in_This_Marksans_Pharma_Analyst_Review\"><\/span><strong>Analyst Insight in This Marksans Pharma Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Senior Research Analyst <strong>Ankit Jaiswal<\/strong> flags Marksans Pharma as a stock to watch in May 2026. At Rs 213.40, Ankit Jaiswal identifies key support in the Rs 158 to Rs 203 band and resistance near Rs 226. He suggests watching Marksans Pharma for a potential move toward Rs 260, subject to Pharmaceuticals &#8211; Generic Formulations sector momentum and Nifty 50 direction. Ankit Jaiswal&#8217;s view is one input in this <strong>Marksans Pharma analyst review<\/strong> and does not constitute a trade recommendation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Technical_Analysis_in_This_Marksans_Pharma_Analyst_Review\"><\/span><strong>Technical Analysis in This Marksans Pharma Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>At Rs 213.40, MARKSANS is trading within its 52-week band of Rs 155.00 to Rs 270.70. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.<\/p>\n<p>Near-term support is identified in the Rs 158 to Rs 203 band while resistance is seen in the Rs 226 to Rs 237 zone. A sustained move above Rs 226 could open the path toward the analyst consensus target of Rs 260.<\/p>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Screen the best stocks on the Univest Screener.<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Support_and_Resistance_Levels\"><\/span><strong>Key Support and Resistance Levels<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Support Zone:<\/strong> Rs 158 to Rs 203 &#8211; investors tracking this <strong>Marksans Pharma analyst review<\/strong> should watch for stabilisation or a bounce in this range as a potential accumulation signal for MARKSANS.<\/li>\n<li><strong>Resistance Zone:<\/strong> Rs 226 to Rs 237 &#8211; a sustained close above Rs 226 would be a positive breakout signal worth flagging in this <strong>Marksans Pharma analyst review<\/strong>.<\/li>\n<li><strong>Medium-Term Target:<\/strong> The analyst consensus of Rs 260 represents the base-case upside scenario identified in this <strong>Marksans Pharma analyst review<\/strong>.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Business_Segment_Analysis\"><\/span><strong>Business Segment Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"US_OTC_Pharmaceuticals_Acetaminophen_Ibuprofen\"><\/span><strong>US OTC Pharmaceuticals (Acetaminophen, Ibuprofen)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This is the primary revenue and margin driver for Marksans Pharma, directly supporting the earnings trajectory toward the consensus target of Rs 260.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"UK_and_European_OTC_Drug_Products\"><\/span><strong>UK and European OTC Drug Products<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This segment adds scale and diversification to Marksans Pharma&#8217;s business model and is a meaningful EPS contributor through FY27 and FY28.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Australia_and_New_Zealand_Regulated_Generics\"><\/span><strong>Australia and New Zealand Regulated Generics<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This represents the medium-term growth frontier for Marksans Pharma and a key re-rating catalyst for the stock over the next 12 to 24 months.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Valuation_in_This_Marksans_Pharma_Analyst_Review\"><\/span><strong>Valuation in This Marksans Pharma Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>At Rs 213.40, Marksans Pharma trades at a trailing P\/E of 25x. This <strong>Marksans Pharma analyst review<\/strong> presents three valuation scenarios: a bull case of Rs 320 on strong earnings delivery and sector tailwinds, a base case of Rs 260 at analyst consensus, and a bear case of Rs 165 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this <strong>Marksans Pharma analyst review<\/strong>.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Scenario<\/th>\n<th>Target Price<\/th>\n<th>Key Condition<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 320<\/td>\n<td>Strong earnings delivery and sector re-rating<\/td>\n<\/tr>\n<tr>\n<td>Base Case (Consensus)<\/td>\n<td>Rs 260<\/td>\n<td>Moderate growth, analyst consensus estimate<\/td>\n<\/tr>\n<tr>\n<td>Bear Case<\/td>\n<td>Rs 165<\/td>\n<td>Earnings miss or macro headwinds<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Trade_Outlook_for_Marksans_Pharma\"><\/span><strong>Trade Outlook for Marksans Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Based on the technical and fundamental analysis in this <strong>Marksans Pharma analyst review<\/strong>, investors might watch MARKSANS near the support zone of Rs 158 to Rs 203 for potential opportunities. A flag above Rs 226 could suggest improving momentum toward Rs 260. This article uses watch-and-flag language only and does not constitute a trade recommendation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_for_Marksans_Pharma_in_FY27\"><\/span><strong>Key Risks for Marksans Pharma in FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>A well-rounded <strong>Marksans Pharma analyst review<\/strong> must assess downside risks. Key risks for Marksans Pharma include a macro slowdown affecting Pharmaceuticals &#8211; Generic Formulations sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in MARKSANS.<\/p>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to get daily stock recommendations and expert research.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_Marksans_Pharma_Analyst_Review_Verdict_for_2026\"><\/span><strong>Conclusion: Marksans Pharma Analyst Review Verdict for 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This <strong>Marksans Pharma analyst review<\/strong> concludes that at Rs 213.40, MARKSANS offers a defined risk-reward with a consensus target of Rs 260. The 52-week range of Rs 155.00 to Rs 270.70 provides context on the current entry point. Use this <strong>Marksans Pharma analyst review<\/strong> as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on MARKSANS.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_Marksans_Pharma_Analyst_Review_2026\"><\/span><strong>Frequently Asked Questions: Marksans Pharma Analyst Review 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_analyst_target_for_Marksans_Pharma_in_2026\"><\/span><strong>What is the analyst target for Marksans Pharma in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The analyst consensus target is Rs 260, with a bull case of Rs 320 and a bear case of Rs 165. Monitor Q1 FY27 earnings for confirmation as highlighted in this <strong>Marksans Pharma analyst review<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Marksans_Pharma_a_good_investment_at_Rs_21340\"><\/span><strong>Is Marksans Pharma a good investment at Rs 213.40?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At Rs 213.40 with a P\/E of 25x and a consensus target of Rs 260, this <strong>Marksans Pharma analyst review<\/strong> is constructive for medium to long-term investors in the Pharmaceuticals &#8211; Generic Formulations sector. Always consult a SEBI-registered advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Marksans_Pharmas_52-week_high_and_low\"><\/span><strong>What is Marksans Pharma&#8217;s 52-week high and low?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 52-week high is Rs 270.70 and the 52-week low is Rs 155.00. At Rs 213.40, MARKSANS is positioned within this range as noted in this <strong>Marksans Pharma analyst review<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_for_Marksans_Pharma\"><\/span><strong>What are the key risks for Marksans Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals &#8211; Generic Formulations sector as assessed in this <strong>Marksans Pharma analyst review<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Where_can_I_track_live_data_for_Marksans_Pharma\"><\/span><strong>Where can I track live data for Marksans Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Track Marksans Pharma&#8217;s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this <strong>Marksans Pharma analyst review<\/strong>.<\/p>\n<p><em>Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Marksans Pharma analyst review 2026: CMP Rs 213.40, MCap Rs 8,500 Cr, PE 25x. Pharmaceuticals &#8211; Generic Formulations outlook and technical levels. May 2026.<\/p>\n","protected":false},"author":28,"featured_media":90667,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-90544","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1779092121:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["82"],"rank_math_title":["Marksans Pharma Analyst Review 2026: Key Levels and Outlook"],"rank_math_description":["Marksans Pharma analyst review 2026: CMP Rs 213.40, MCap Rs 8,500 Cr, PE 25x. Pharmaceuticals - Generic Formulations outlook and technical levels. May 2026."],"rank_math_focus_keyword":["Marksans Pharma Analyst Review"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["90667"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["12048"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/18134442\/Marksans-Pharma-Analyst-Review.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/90544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=90544"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/90544\/revisions"}],"predecessor-version":[{"id":90668,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/90544\/revisions\/90668"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/90667"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=90544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=90544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=90544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}